FDA continues to review Daiichi Sankyo and Lilly’s prasugrel NDA
The proposed indication for prasugrel is for the treatment of patients with acute coronary syndromes being managed with an artery-opening procedure known as percutaneous coronary intervention. Daiichi Sankyo
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.